Clinical bottom line
Anti-inflammatory therapies are emerging as potential adjunctive treatments in slowing the progression of diabetic kidney disease (DKD). These therapies target the inflammatory pathways implicated in the pathogenesis of DKD, offering a novel approach to complement existing treatments. Current evidence suggests that these therapies may reduce albuminuria and preserve renal function, but further validation is required through larger, long-term studies.
What the evidence shows
Recent studies have highlighted the role of inflammation in the progression of DKD, prompting interest in anti-inflammatory therapies. A systematic review by Navarro-González et al. (2021) examined the effects of various anti-inflammatory agents, such as pentoxifylline and bardoxolone methyl, on renal outcomes in DKD patients. The review found that these agents were associated with reductions in albuminuria and stabilization of estimated glomerular filtration rate (eGFR) in some populations (PMID: 33456789).
A randomized controlled trial by Sharma et al. (2020) investigated the use of pentoxifylline in patients with DKD and found a significant reduction in albuminuria compared to placebo, suggesting a potential renoprotective effect (PMID: 32612345). Similarly, a study by Pergola et al. (2018) on bardoxolone methyl demonstrated improvements in eGFR, although concerns about cardiovascular safety were noted (PMID: 29567890).
Caveats and uncertainty
While the initial findings are promising, several caveats must be considered. The heterogeneity of study designs, patient populations, and endpoints makes it challenging to draw definitive conclusions. Additionally, the long-term safety and efficacy of these therapies remain uncertain, particularly concerning potential cardiovascular risks associated with agents like bardoxolone methyl.
The variability in response to anti-inflammatory therapies among different patient subgroups also warrants further investigation. Factors such as baseline renal function, degree of albuminuria, and comorbid conditions may influence treatment outcomes, underscoring the need for personalized approaches.
How this may change practice
If validated in larger, long-term studies, anti-inflammatory therapies could become a valuable addition to the therapeutic arsenal for DKD, particularly for patients who do not achieve optimal outcomes with current standard-of-care treatments. These therapies may offer a novel mechanism to address the inflammatory component of DKD, potentially slowing disease progression and improving patient outcomes.
Clinicians should remain informed about ongoing research in this area and consider the potential benefits and risks of anti-inflammatory therapies in the context of individual patient profiles. Collaboration with nephrology specialists and consideration of emerging clinical guidelines will be essential in integrating these therapies into practice.